CRISPR Therapeutics AG

115.74-4.64-3.85%Vol 1.06M1Y Perf 152.17%
Apr 9th, 2021 16:00 DELAYED
BID114.40 ASK115.52
Open119.28 Previous Close120.38
Pre-Market- After-Market-
 - -  - -%
Target Price
155.47 
Analyst Rating
Moderate Buy 2.09
Potential %
34.33 
Finscreener Ranking
★★+     48.13
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.36
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     51.51
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap8.73B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
41.11 
Earnings Date
27th Apr 2021

Today's Price Range

114.32119.37

52W Range

42.83220.20

5 Year PE Ratio Range

-13.00185.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.07%
1 Month
-6.77%
3 Months
-40.28%
6 Months
17.79%
1 Year
152.17%
3 Years
134.91%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRSP115.74-4.6400-3.85
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
17.90
18.20
0.03
0.04
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-304.60
-294.20
-10 850.20
7.42
RevenueValueIndustryS&P 500US Markets
562.00K
0.01
-52.77
31.10
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.23-1.50-21.95
Q03 2020-1.17-1.32-12.82
Q02 2020-0.92-1.30-41.30
Q01 2020-1.09-1.15-5.50
Q04 20190.040.511.18K
Q03 2019-0.952.40352.63
Q02 2019-0.81-1.01-24.69
Q01 2019-0.88-0.93-5.68
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.49-13.74Negative
6/2021 QR-1.52-10.14Negative
12/2021 FY-5.84-13.84Negative
12/2022 FY-6.11-18.18Negative
Next Report Date27th Apr 2021
Estimated EPS Next Report-1.49
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1.06M
Shares Outstanding75.43M
Trades Count25.63K
Dollar Volume283.98M
Avg. Volume2.24M
Avg. Weekly Volume951.62K
Avg. Monthly Volume1.44M
Avg. Quarterly Volume2.17M

CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 115.74 per share at the end of the most recent trading day (a -3.85% change compared to the prior day closing price) with a volume of 1.07M shares and market capitalization of 8.73B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.

The one-year performance of CRISPR Therapeutics AG stock is 152.17%, while year-to-date (YTD) performance is -24.41%. CRSP stock has a five-year performance of %. Its 52-week range is between 42.83 and 220.2, which gives CRSP stock a 52-week price range ratio of 41.11%

CRISPR Therapeutics AG currently has a PE ratio of -23.00, a price-to-book (PB) ratio of 5.52, a price-to-sale (PS) ratio of 16 026.60, a price to cashflow ratio of 111.30, a PEG ratio of 2.32, a ROA of -23.34%, a ROC of -20.86% and a ROE of -25.97%. The company’s profit margin is 7.42%, its EBITDA margin is -294.20%, and its revenue ttm is $562.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from CRISPR Therapeutics AG, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.49 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is 27th Apr 2021.

The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (2.09), with a target price of $155.47, which is +34.33% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CRISPR Therapeutics AG has a Sell technical analysis rating based on Technical Indicators (ADX : 23.96, ATR14 : 12.07, CCI20 : -63.73, Chaikin Money Flow : -0.02, MACD : -12.57, Money Flow Index : 34.55, ROC : -9.33, RSI : 36.58, STOCH (14,3) : 49.08, STOCH RSI : 1.00, UO : 51.28, Williams %R : -50.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Bradley J. Bolzon (Option Excercise at a value of $1 309 650), Bradley J. Bolzon (Sold 596 381 shares of value $77 802 321 ), James R. Kasinger (Option Excercise at a value of $1 715 969), James R. Kasinger (Sold 27 500 shares of value $5 635 943 ), Lawrence Otto Klein (Option Excercise at a value of $3 808 226), Lawrence Otto Klein (Sold 220 000 shares of value $25 006 712 ), Michael Tomsicek (Option Excercise at a value of $426 000), Michael Tomsicek (Sold 21 200 shares of value $1 887 083 ), Rodger Novak (Option Excercise at a value of $2 073 215), Rodger Novak (Sold 350 000 shares of value $30 325 597 ), Samarth Kulkarni (Option Excercise at a value of $130 818), Samarth Kulkarni (Sold 72 275 shares of value $9 215 040 ), Tony W. Ho (Option Excercise at a value of $398 012), Tony W. Ho (Sold 37 409 shares of value $4 521 617 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (63.64 %)
6 (60.00 %)
6 (60.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (18.18 %)
2 (20.00 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (18.18 %)
2 (20.00 %)
2 (20.00 %)
Summary RatingModerate Buy
2.09
Moderate Buy
2.20
Moderate Buy
2.20

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

CEO: Samarth Kulkarni

Telephone: +41 415613277

Address: Baarerstrasse 14, Zug 6300, , CH

Number of employees: 410

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

68%32%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

News

Stocktwits